Kardatuxan

Rivaroxaban, the active ingredient in Kardatuxan, is a direct factor Xa inhibitor presented as an oral tablet for oral use. It is indicated for the prevention of stroke and systemic embolism in patients with non‑valvular atrial fibrillation and for the treatment and secondary prevention of deep vein thrombosis and pulmonary embolism in adult patients under medical supervision as prescribed by a healthcare professional.

GNH USA supplies Kardatuxan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kardatuxan (rivaroxaban) is used in the anticoagulation pathway to reduce thrombus formation.

- Non‑valvular atrial fibrillation: reduces risk of stroke and systemic embolism. - Deep vein thrombosis: treats acute clot and prevents recurrence. - Pulmonary embolism: facilitates clot resolution and lowers recurrence risk. - Secondary prevention of venous thromboembolism: maintains anticoagulation after initial treatment.

Common Side Effects: - Minor bleeding (e.g., gum or nosebleeds). - Bruising at sites of minor trauma. - Gastrointestinal discomfort or dyspepsia. - Headache. - Dizziness.

Serious or Rare Side Effects: - Major hemorrhage (intracranial, gastrointestinal, or fatal bleeding). - Spinal or epidural hematoma, especially after neuraxial procedures. - Hepatic injury with elevated transaminases. - Severe allergic reactions such as anaphylaxis.

Before initiating therapy, evaluate patient-specific risk factors and monitor appropriately. - Renal function assessment: adjust use in severe impairment. - Bleeding risk evaluation: avoid in active bleeding conditions. - Concomitant antiplatelet therapy: assess increased bleeding potential. - Surgery or invasive procedures: discontinue as recommended prior to the procedure. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Rivaroxaban may interact with several medicines that affect hemostasis or drug metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Other anticoagulants (e.g., warfarin, heparin): additive bleeding risk. - Antiplatelet agents (e.g., clopidogrel, aspirin): heightened bleeding potential.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may raise exposure. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase gastrointestinal bleeding risk. - Selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline): potential for enhanced bleeding.